BP720

Verapamil hydrochloride

British Pharmacopoeia (BP) Reference Standard

• Synonyme(s) : (±)-Verapamil hydrochloride, 5-[N-(3,4-Dimethoxyphenylethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile hydrochloride
• Formule linéaire : (CH₃O)₂C₆H₃CH₂CH₂N(CH₃)(CH₂)₃C[C₆H₃(OCH₃)₂][CH(CH₃)₂]CN · HCl
• Numéro CAS: 152-11-4
• Poids moléculaire : 491.06
• Numéro Beilstein : 3647093
• Numéro MDL: MFCD00055208
• Code UNSPSC : 41116107
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: pharmaceutical primary standard
• Famille d'API: verapamil
• Forme: solid
• Durée de conservation: limited shelf life, expiry date on the label
• Fabricant/nom de marque: BP
• Pf: 142 °C (dec.) (lit.)
• Application(s): pharmaceutical; pharmaceutical small molecule
• Format: neat
• Température de stockage: 2-8°C
• Chaîne SMILES: Cl.COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC
• InChI: 1S/C27H38N2O4.ClH/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6;/h9-12,17-18,20H,8,13-16H2,1-7H3;1H
• Clé InChI: DOQPXTMNIUCOSY-UHFFFAOYSA-N
• Informations sur le gène: human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)

Description

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Verapamil hydrochloride BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.

Also used in monographs such as:

Verapamil Prolonged-release Tablets

Verapamil Tablets

Verapamil Oral Solution

Verapamil Prolonged-release Capsules

Verapamil Injection

Actions biochimiques/physiologiques

α₁-adrenoceptor antagonist; L-type calcium channel blocker. Blocks L-type Ca²⁺ channels in smooth and cardiac muscle, induces apoptosis of human primary and metastatic colon adenocarcinoma cells in vitro. Drug resistance reversal agent acting on Pgp, e.g. decrease renal tubule elimination of digoxin. Increases basal ATPase activity of Pgp. Substrate of Cyp3A4 and CYP2C6.

Conditionnement

Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

Autres remarques

Sales restrictions may apply.

Informations sur la sécurité

• Pictogrammes: GHS06,GHS09
• Mention d'avertissement: Danger
• Mentions de danger: H301,H411
• Conseils de prudence: P264 - P273 - P301 + P310 - P391 - P405 - P501
• Classification des risques: Acute Tox. 3 Oral - Aquatic Chronic 2
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable